GeekWire

JANUARY 13, 2021

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. Sana, which is developing gene and cell therapies that could be used to combat a variety of diseases, previously raised more than $700 million in venture capital. Sana CEO Steve Harr (Sana photo). stake in Sana.

Biotechnology 131

Biotechnology Applications .Net Company 131

GeekWire

JULY 7, 2021

The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Net losses were $5.3

Development 141

Development Biotechnology Pharmaceuticals .Net 141

CTOvision

FEBRUARY 10, 2016

The technology was developed under DARPA’s Reliable Neural-Interface Technology (RE-NET) program , and offers new potential for safely expanding the use of brain-machine interfaces (BMIs) to treat physical disabilities and neurological disorders.

.Net 150

.Net Biotechnology Research Study 150

GeekWire

FEBRUARY 8, 2021

Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo). It values the company at $900 million.

Biotechnology 145

Biotechnology .Net Groups Company 145

Trends in the Living Networks

AUGUST 11, 2022

She has worked on projects about diverse issues such as water security, the future of energy, the future of youth, intelligent buildings, the development of cities over the next few decades, and planning for Egypt in 2030. Chung developed the curriculum and conducted training for the government’s in-house futures course, Futurecraft.

Study 148

Study Research Trends Education 148